Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Détails
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_57E1389C4D3F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Périodique
Redox biology
ISSN
2213-2317 (Electronic)
ISSN-L
2213-2317
Statut éditorial
Publié
Date de publication
04/2025
Peer-reviewed
Oui
Volume
81
Pages
103569
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo.
Mots-clé
NF-E2-Related Factor 2/metabolism, Humans, Oxidation-Reduction, Noncommunicable Diseases/drug therapy, Oxidative Stress/drug effects, Animals, Neoplasms/metabolism, Neoplasms/drug therapy, Neoplasms/pathology, Drug repurposing, GSK-3, KEAP1, NRF2 diseasome, β-TrCP
Pubmed
Open Access
Oui
Création de la notice
14/03/2025 16:54
Dernière modification de la notice
25/03/2025 8:12